

RE

10-26-2004



102867544

HEET

10-22-04

To the Director of the U.S.

Attached documents or the new address(es) below.

1. Name of conveying party, _____, Execution Date(s): _____

Novartis AG

4-15-04

Execution Date(s) March 4, 2004

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment Merger
- Security Agreement Change of Name
- Government Interest Assignment
- Executive Order 9424, Confirmatory License
- Other _____

2. Name and address of receiving party(ies)

Name: Syngenta Participations AG

Internal Address: _____

Street Address: Schwarzwaldalle 215

Basel, Switzerland 4058

City: _____

State: _____

Country: _____

Zip: _____

Additional name(s) & address(es) attached? Yes No

4. Application or patent number(s):

This document is being filed together with a new application.

A. Patent Application No.(s)

09/604,588

B. Patent No.(s)

6,353,157

Additional numbers attached? Yes No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Larry W. Stults

Internal Address: Syngenta Biotechnology Inc.

Street Address: 3054 Cornwallis Road

City: RTP

State: NC

Zip: 27709

Phone Number: _____

Fax Number: _____

Email Address: _____

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 1.21(h) & 3.41) \$ _____

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed
- None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number _____
Authorized User Name _____

9. Signature: _____

Bruce Vrana
Signature

10/20/2004
Date

Bruce Vrana

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

8

Documents to be recorded (including cover sheet) should be faxed to (703) 306-6996, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1460, Alexandria, V.A. 22313-1460

ASSIGNMENT

NOVARTIS AG, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056,


for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, hereby assigns to **Syngenta Participations AG**, a Swiss corporation, having a place of business at Schwarzwaldalle 215, Basel, Switzerland 4058, its successors, assigns and legal representatives, all right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the inventions described in the applications for United States Letters Patent


Atty. Docket No.	Application Ser. No.	Filing date	Patent No.	Issue date
135-2015	09/330,737	11/JUN/1999	6,232,534	15/MAY/2001
135-2015	09/330,760	11/JUN/1999	6,229,075	08/MAY/2001
135-2015	09/328,473	09/JUN/1999	6,232,533	15/MAY/2001
135-2015	09/328,826	09/JUN/1999	6,399,860	04/JUN/2002
135-2015	09/291,238	13/APR/1999	6,222,104	24/APR/2001
135-2015	09/289,010	09/APR/1999	6,437,223	20/AUG/2002
135-2015	09/042,426	13/MAR/1998	6,114,608	05/SEP/2000
135-2014	08/802,021	18/FEB/1997	5,824,852	20/OCT/1998
135-2011	08/780,195	10/JAN/1997	5,811,645	22/SEP/1998
135-2010	08/780,568	08/JAN/1997	6,187,999	13/FEB/2001
135-2001	08/728,715	11/OCT/1996	6,156,957	05/DEC/2000
130-4080	09/001,982	31/DEC/1997	6,204,246	20/MAR/2001
31475	09/603,491	23/JUN/2000	6,350,938	26/FEB/2002
31474	09/605,159	28/JUN/2000	6,426,449	30/JUL/2002
31473	09/598,756	22/JUN/2000	6,346,659	12/FEB/2002
31386	09/598,755	22/JUN/2000	6,350,937	26/FEB/2002
31385	09/604,588	27/JUN/2000	6,353,157	05/MAR/2002
31379	09/575,631	22/MAY/2000	6,362,402	26/MAR/2002
30959	09/309,038	10/MAY/1999		
30910	09/364,849	30/JUL/1999	6,166,304	26/DEC/2000


Atty. Docket No.	Application Ser. No.	Filing date	Patent No.	Issue date
30905	09/318,103	24/MAY/1999	5,990,395	23/NOV/1999
30904	09/318,102	24/MAY/1999	6,034,306	07/MAR/2000
30903	09/317,334	24/MAY/1999	6,188,003	13/FEB/2001
30901	US00/11460	28/APR/2000		
30884	09/502,852	11/FEB/2000		
30850	09/262,399	04/MAR/1999	6,140,563	31/OCT/2000
30833	09/251,922	17/FEB/1999	6,297,430	02/OCT/2001
30832	09/251,308	17/FEB/1999	6,204,438	20/MAR/2001
30819	09/250,233	15/FEB/1999	6,040,502	21/MAR/2000
30818	09/250,211	15/FEB/1999	6,037,528	14/MAR/2000
30817	09/249,037	12/FEB/1999	6,066,784	23/MAY/2000
30816	09/249,214	12/FEB/1999	6,084,158	04/JUL/2000
30815	09/249,125	12/FEB/1999	6,040,501	21/MAR/2000
30814	09/248,453	11/FEB/1999	6,063,991	16/MAY/2000
30793	09/240,167	29/JAN/1999	6,184,444	06/FEB/2001
30792	09/240,405	29/JAN/1999	6,169,233	02/JAN/2001
30786	09/234,274	19/JAN/1999	6,072,110	06/JUN/2000
30511	09/053,349	01/APR/1998	6,121,521	19/SEP/2000


including (1) said applications for United States Letters Patent and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Novartis Finance Corporation and its successors and assigns to the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by assignor if this sale, assignment and transfer had not been made;

And assignor hereby agrees to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this 4th day of March, 2004 by 
Werner Bastian (on behalf of Novartis AG)

Signed this 4th day of March, 2004 by 
Lilly Sitzler Spicher (on behalf of Novartis AG)

Signed this 4th day of March, 2004 by 
Jocelyne Ceroni (on behalf of Syngenta Participations AG)

Signed this 4th day of March, 2004 by 
Cornelia Ebinger-Zöld (on behalf of Syngenta Participations AG)